{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:07:01Z","timestamp":1792951621935,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ebiom.2024.105554","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T17:51:39Z","timestamp":1736790699000},"page":"105554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCS"],"prefix":"10.1016","volume":"112","author":[{"given":"Jacob S.","family":"Bedia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Gentry-Maharaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Burnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveena","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Manchanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatinderpal K.","family":"Kalsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Dawnay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Fallowfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair J.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh K.B.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9249-4316","authenticated-orcid":false,"given":"Steven J.","family":"Skates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2024.105554_bib1","series-title":"Ovarian cancer statistics","year":"2015"},{"key":"10.1016\/j.ebiom.2024.105554_bib2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2024.105554_bib3","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2024.105554_bib4","doi-asserted-by":"crossref","first-page":"251S","DOI":"10.1016\/S0197-2456(00)00097-0","article-title":"The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status","volume":"21","author":"Gohagan","year":"2000","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ebiom.2024.105554_bib5","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2022008","article-title":"Quantifying the duration of the preclinical detectable phase in cancer screening: a systematic review","volume":"44","author":"Geurts","year":"2022","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.ebiom.2024.105554_bib6","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-15-2750","article-title":"Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk \u2013 combined results from two screening trials","volume":"23","author":"Skates","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2024.105554_bib7","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1200\/JCO.2016.69.9330","article-title":"Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study","volume":"35","author":"Rosenthal","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2024.105554_bib8","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ebiom.2024.105554_bib9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ygyno.2020.05.002","article-title":"Ovarian cancer symptoms, routes to diagnosis and survival \u2013 population cohort study in the \u2018no screen\u2019 arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)","volume":"158","author":"Dilley","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ebiom.2024.105554_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ygyno.2023.11.005","article-title":"Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer \u2013 an exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)","volume":"179","author":"Dilley","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ebiom.2024.105554_bib11","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(23)00335-2","article-title":"Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial","volume":"24","author":"Menon","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ebiom.2024.105554_bib12","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1198\/016214501753168145","article-title":"Screening based on the risk of cancer calculation from Bayesian hierarchical changepoint and mixture models of longitudinal markers","volume":"96","author":"Skates","year":"2001","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ebiom.2024.105554_bib13","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1016\/j.molcel.2021.10.013","article-title":"A\u00a0multi-omic single-cell landscape of human gynecologic malignancies","volume":"81","author":"Regner","year":"2021","journal-title":"Mol Cell"},{"key":"10.1016\/j.ebiom.2024.105554_bib14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2024.105554_bib15","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/bjc.2012.68","article-title":"The Aarhus statement: improving design and reporting of studies on early cancer diagnosis","volume":"106","author":"Weller","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ebiom.2024.105554_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.humrep.a136832","article-title":"The CA 125 tumour-associated antigen: a review of the literature","volume":"4","author":"Jacobs","year":"1989","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ebiom.2024.105554_bib17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijgo.2007.06.003","article-title":"Serum CA125 level before the development of ovarian cancer","volume":"99","author":"Kobayashi","year":"2007","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.ebiom.2024.105554_bib18","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/jnci\/djae145","article-title":"Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework","volume":"116","author":"Ishizawa","year":"2024","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ebiom.2024.105554_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156661","article-title":"Modeling the dynamics of high-grade serous ovarian cancer progression for transvaginal ultrasound-based screening and early detection","volume":"11","author":"Botesteanu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2024.105554_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050170","article-title":"Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes","volume":"5","author":"Lutz","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.ebiom.2024.105554_bib21","first-page":"1","article-title":"Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial","author":"Menon","year":"2023","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ebiom.2024.105554_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000114","article-title":"The preclinical natural history of serous ovarian cancer: defining the target for early detection","volume":"6","author":"Brown","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ebiom.2024.105554_bib23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2024.105554_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5219","article-title":"Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions","volume":"248","author":"Wu","year":"2019","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.ebiom.2024.105554_bib25","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/IGC.0b013e3182a80ac8","article-title":"Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC)","volume":"23","author":"Wethington","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ebiom.2024.105554_bib26","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2014.59.4945","article-title":"Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening","volume":"33","author":"Menon","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ebiom.2024.105554_bib27","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3390\/cancers12071931","article-title":"Multi-marker longitudinal algorithms incorporating HE4 and CA125 in ovarian cancer screening of postmenopausal women","volume":"12","author":"Gentry-Maharaj","year":"2020","journal-title":"Cancers Basel"},{"key":"10.1016\/j.ebiom.2024.105554_bib28","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1158\/2159-8290.CD-23-0313","article-title":"Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multicancer biomarker","volume":"13","author":"Taylor","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ebiom.2024.105554_bib29","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.3390\/cancers14122885","article-title":"Current and emerging methods for ovarian cancer screening and diagnostics: a comprehensive review","volume":"14","author":"Liberto","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ebiom.2024.105554_bib30","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2767-9764.CRC-22-0314","article-title":"Uterine lavage identifies cancer mutations and increased TP53 somatic mutation burden in individuals with ovarian cancer","volume":"2","author":"Ghezelayagh","year":"2022","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.ebiom.2024.105554_bib31","first-page":"517","article-title":"Prognostically relevant gene signatures of high-grade serous ovarian carcinoma","volume":"123","author":"Verhaak","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ebiom.2024.105554_bib32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s12094-015-1441-5","article-title":"CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review","volume":"18","author":"Colloca","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ebiom.2024.105554_bib33","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41416-022-01844-0","article-title":"Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP)","volume":"127","author":"Menon","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ebiom.2024.105554_bib34","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.3390\/cancers12123730","article-title":"CA125 and ovarian cancer: a comprehensive review","volume":"12","author":"Charkhchi","year":"2020","journal-title":"Cancers Basel"},{"key":"10.1016\/j.ebiom.2024.105554_bib35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/GCO.0000000000000340","article-title":"Pathogenesis and heterogeneity of ovarian cancer","volume":"29","author":"Kroeger","year":"2017","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.ebiom.2024.105554_bib36","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11912-014-0389-x","article-title":"Mucinous tumors of the ovary: current thoughts on diagnosis and management","volume":"16","author":"Brown","year":"2014","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ebiom.2024.105554_bib37","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1158\/1055-9965.EPI-09-0750","article-title":"Clinical presentation of endometrioid epithelial ovarian cancer with concurrent endometriosis: a multicenter retrospective study","volume":"19","author":"Lim","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ebiom.2024.105554_bib38","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ebiom.2024.105554_bib39","first-page":"489","article-title":"Factors influencing serum CA125II levels in healthy postmenopausal Women 1","volume":"10","author":"Pauler","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ebiom.2024.105554_bib40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5694\/mja2.52227","article-title":"Screening and prevention of ovarian cancer","volume":"220","author":"Sideris","year":"2024","journal-title":"Med J Aust"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424005905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424005905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T03:59:02Z","timestamp":1741924742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396424005905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":40,"alternative-id":["S2352396424005905"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105554","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCS","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105554"}}